RxDoctor Payments Data

Sumeet Soni, MD

Pulmonary Disease · Carbondale, ILNPI 1962885293

Payments from drug & device makers

$2,494in general payments, 2019–2025

Across 133 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$612
  • GSK$383
  • Sanofi$279
  • Mallinckrodt Hospital Products Inc.$230
  • Regeneron Healthcare Solutions, Inc.$214
  • Boehringer Ingelheim$167
  • plus $608 from 11 others

What the payments were for

  • Food & beverage$2,39496%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,494 in reported general payments places this provider in the 55th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$99,667
Medicare patients
408
Services billed
1,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter165$114,668
Dupixent PenDupilumab22$83,177
Breztri AerosphereBudesonide/Glycopyr/Formoterol78$48,462
Breo ElliptaFluticasone/Vilanterol69$33,071
Spiriva RespimatTiotropium Bromide43$25,083
Spiriva HandihalerTiotropium Bromide37$24,240
DuleraMometasone/Formoterol56$23,236
Stiolto RespimatTiotropium Br/Olodaterol Hcl34$17,468
Advair HfaFluticasone Propion/Salmeterol33$14,250
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$12,311
Fluticasone-SalmeterolFluticasone Propion/Salmeterol48$9,561
Incruse ElliptaUmeclidinium Bromide22$9,453
Roflumilast48$6,425
Albuterol Sulfate HfaAlbuterol Sulfate177$5,982
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$5,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$383$169,504273 claims
AstraZenecaBreztri Aerosphere$612$48,46278 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$167$42,55177 claims
MerckDulera$22$23,23656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Carbondale

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →